v3 · in production
7-day report
Life-threatening. Not listed at this severity: the brochure lists aminotransferase increases to grade 2. The suspected viral cause was excluded on follow-up.
4/4
The revised skill scored 92.5%, up from 87.5%. It also missed a life-threatening liver injury that FDA must hear about within 7 days. The release review caught it before the change shipped.
v3 in production, v4 proposed.
sae-02: a 7-day report routed to no report.
Recorded by the drug safety physician (fictional).
Worked example. The sponsor, compound, study and case reports are fictional and contain no patient data. Agent outputs are illustrative. This is not a customer run or a hosted evaluation run.
Four parts of Versalist, one review.
Fixed the test
10 case reports, 4 scored calls per case, and a reference answer that cites the regulation.
Held both versions
v3 in production and v4 proposed, with 3 rules rewritten and 1 added.
Compared them
Same cases, rubric and model. Expectedness flagged as a regression; sae-02 dropped from 4 to 1.
Stopped the release
Needs work, recorded by the drug safety physician (fictional) and saved with the evidence.
v4 gains 5 points by no longer filing the 4 reports that v3 files without needing to (sae-01, sae-03, sae-09, sae-10). It loses 3 on sae-02, the one required report it misses. The total rises from 35 to 37 of 40 points.
| Case | Correct route | v3 (in production) | v4 (proposed) |
|---|---|---|---|
| sae-01Diarrhea, grade 3 | No report | 15-day report · not required · 3/4 | No report · 4/4 |
| sae-02Hepatocellular injury with jaundice | 7-day report | 7-day report · 4/4 | No report · missed · 1/4 (regression) |
| sae-03Death due to disease progression | No report | 7-day report · not required · 2/4 | No report · 4/4 |
| sae-04Femoral neck fracture after a fall | No report | No report · 4/4 | No report · 4/4 |
| sae-05Pneumonitis, grade 3 | 15-day report | 15-day report · 4/4 | 15-day report · 4/4 |
| sae-06Rash maculo-papular, grade 2 | No report | No report · 4/4 | No report · 4/4 |
| sae-07Generalized tonic-clonic seizure | 15-day report | 15-day report · 4/4 | 15-day report · 4/4 |
| sae-08Anaphylaxis | 7-day report | 7-day report · 4/4 | 7-day report · 4/4 |
| sae-09Neutrophil count decreased, grade 3 | No report | 15-day report · not required · 3/4 | No report · 4/4 |
| sae-10ALT and AST increased, grade 2 | No report | 15-day report · not required · 3/4 | No report · 4/4 |
The review flags expectedness as a regression (10 → 9 of 10). Causality looks unchanged at 9 of 10, but that nets out a case v4 fixed (sae-03) and one it broke (sae-02).
A trial participant develops jaundice on day 29, with liver enzymes above 12 times normal and no other cause found. That is a potential Hy’s Law case, which FDA treats as a strong signal of severe drug-induced liver injury. It needs a 7-day report, due .
v3 · in production
Life-threatening. Not listed at this severity: the brochure lists aminotransferase increases to grade 2. The suspected viral cause was excluded on follow-up.
4/4
v4 · proposed
Expected: the brochure lists ALT increased and AST increased, which are liver events. Not suspected: the investigator assessed the event as not related.
1/4
v4 sends the case to the monthly aggregate queue instead. FDA and the other trial investigators would not hear about it in time, while patients in the same cohort keep taking the drug.
Expectedness: “An event is expected if the investigator brochure lists an adverse reaction in the same organ system.”
21 CFR 312.32(a) makes an event unexpected when it is not listed at the specificity or severity observed. Its own example: hepatic necrosis is unexpected if the brochure refers only to elevated hepatic enzymes or hepatitis.
Causality: “Use the investigator's causality assessment.”
FDA's December 2025 guidance: the sponsor must report events for which the investigator's assessment is negative for causality but the sponsor's evaluation found evidence to suggest a causal relationship.
A 54-year-old woman with breast cancer that has not spread to her liver develops jaundice on day 29 of treatment. The investigator suspects viral hepatitis and reports the event as not related to the drug. Follow-up tests rule out viral, autoimmune and biliary causes, but the assessment is never updated.
| Test | Screening | Day 29 | × ULN |
|---|---|---|---|
| ALT | 22 U/L | 612 U/L | 15.3 |
| AST | 25 U/L | 498 U/L | 12.5 |
| Total bilirubin | 0.6 mg/dL | 4.1 mg/dL | 3.4 |
| Alkaline phosphatase | 88 U/L | 162 U/L | 1.3 |
| INR | 1.0 | 1.9 | — |
Upper limits of normal (ULN): ALT 40 U/L, AST 40 U/L, total bilirubin 1.2 mg/dL, alkaline phosphatase 125 U/L.
The sponsor first received the report on , which starts the 7-day clock.
Needs work
Recorded by the drug safety physician (fictional) ·
Do not ship v4. It misses the 7-day report on sae-02. Keep the routing rule and the anticipated-SAE rule. Restore expectedness at the specificity and severity in the brochure. Make causality the sponsor's evaluation: consider the investigator's assessment, but do not adopt it. Keep v3 in production until the revision scores 4 of 4 on every case that needs an IND safety report.
The next revision runs on the same 10 cases against v3, so every change is judged by the same test.
The regulation, the rule changes and every case, for reviewers who want to check the work.
EX-101 is a fictional cancer drug in its first trial in people. When a trial site reports a serious adverse event, the sponsor’s safety agent decides whether FDA needs an IND safety report, and how quickly. A drug safety physician signs off every report before it is sent.
A report is required only when the event is serious, unexpected (the investigator brochure does not list it at that severity) and a suspected adverse reaction. The deadline depends on how severe the event is. On each case the agent makes those three calls plus the route, and each correct call scores one point.
| Route | When | Deadline |
|---|---|---|
| 7-day IND safety report21 CFR 312.32(c)(2) | Unexpected fatal or life-threatening suspected adverse reaction | 7 calendar days after the sponsor's initial receipt of the information |
| 15-day IND safety report21 CFR 312.32(c)(1)(i) | Any other serious and unexpected suspected adverse reaction | 15 calendar days after the sponsor determines that the information qualifies |
| No IND safety report21 CFR 312.33; 312.32(c)(1)(i)(C) | The event is not serious, not unexpected, or not a suspected adverse reaction | Periodic reporting, such as the IND annual report. Anticipated SAEs go to aggregate analysis. |
The rubric scores a wrong route the same way whether the agent files a report FDA did not need or misses one it did. Only the missed report breaks 21 CFR 312.32, which is why the review owner reads the case rows and not only the total.
v3 is in production, and it over-reports. It files a 15-day report for every serious event the drug may have caused, even when the brochure already lists that reaction, and it treats every death as drug-related. v4 was written to stop filing reports that fail any of the three tests.
Expectedness
v3An event is unexpected if the investigator brochure does not list it at the specificity and severity observed.
v4An event is expected if the investigator brochure lists an adverse reaction in the same organ system.
Causality
v3Treat the event as a suspected adverse reaction unless the report documents another cause.
v4Use the investigator's causality assessment.
Routing
v3Report every serious suspected adverse reaction within 15 calendar days. Treat every death as a suspected adverse reaction. Report deaths and life-threatening events within 7 calendar days.
v4Report only events that are serious, unexpected and suspected: within 7 calendar days if fatal or life-threatening, otherwise within 15.
Anticipated events
v3No rule.
v4Do not report anticipated SAEs, such as death from disease progression, as individual cases. Send them to aggregate review.
Unchanged: seriousness.
Each case tests one rule, and every reference answer cites the regulation or FDA guidance it rests on. The investigator brochure lists these reactions, graded by CTCAE v5.0: diarrhea (grade 1–3), nausea (grade 1–2), vomiting (grade 1–2), fatigue (grade 1–2), rash maculo-papular (grade 1–2), alanine aminotransferase increased (grade 1–2), aspartate aminotransferase increased (grade 1–2), neutrophil count decreased (grade 1–3).